About Alzheimer’s

Alzheimer’s Disease (AD) is a progressive brain disease that slowly destroys memory and thinking skills. It is the most common cause of dementia among older people, with symptoms often appearing by the age of 60. The effects are loss of cognitive function such as thinking, remembering and reasoning to the extent of interfering with a person’s daily life.

  • Amyloid plaques deposited in the brain are believed to precede the onset of dementia by many years. These plaques are seeded by the “bad amyloid” (Αβ42), and cause or contribute to the cognitive decline of AD patients.
  • Alzheimer’s Disease afflicts more than 5.3 million Americans (33 million worldwide) at an annual cost of 200 billion dollars.
  • New cases of Alzheimer’s Disease are on the rise, and it is projected that by 2020 nearly 6 million people in the US will be initially diagnosed with Alzheimer’s dementia.
  • Early preventative treatment is dependent on the diagnosis of amyloid plaque pathology before dementia.
  • Amyloid plaques may be prevented and dementia avoided with the right medicine

Our Technology

Our patented technology of Gamma-Secretase Modulators (GSMs) is based on an innovative modulation of a key enzyme in the amyloid pathway, called γ-secretase. Our approach alters the production of amyloid proteins from the toxic form found in AD brains (Αβ42) to non-toxic forms (Αβ37 and Αβ38), which do not contribute to plaque deposition.

The GSM approach avoids inhibition of other γ-secretase targets potentially minimizing adverse side-effects. Therapies based on these compounds may be used to treat a broad range of amyloid-based diseases including cerebral vascular dementia, inclusion body myositis, Alzheimer’s dementia associated with Down’s Syndrome patients, and more.

Our Product

NGP has selected a clinical candidate, NGP 555, which is a small molecule modulator of the gamma-secretase complex. NGP 555 is a potent molecule, which crosses the blood-brain barrier and is effective in lowering the brain biomarkers Αβ42 and Αβ40 while showing an increase in the Αβ38 peptide with no effect on Notch processing. A key “proof of concept” study with NGP 555 showed significant reduction of amyloid plaques in the brains of mice harboring the human amyloid precursor protein.

NGP 555 represents a unique opportunity to clinically translate these biomarker findings to the reduction of amyloid pathology, culminating in the prevention of cognitive decline in Alzheimer’s Disease.


Mechanism of action, method of treatment, and solid dosage form formulations for oral dosing.

U.S.Patent 7,244,739 plus EPO, India, China, Canada, Mexico and other territories
U.S.Patent 7,781,442
U.S.Patent 7,799,808
U.S.Patent 8,017,629


Kounnas, MZ, Lane-Donovan, C, Nowakowski, DW, Herz J, Comer WT: “ Get the facts NGP 555, a gamma-Secretase Modulator, Lowers the Amyloid Biomarker, Abeta42,  in Cerebrospinal Fluid while Preventing Alzheimer’s Disease Amyloid Pathology and Cognitive Decline in RodentsAlzheimer’s and Dementia: TCRI, December, 2016.

Maria Z. Kounnas et. al. Neuron 67, 769-780, September 9, 2010.

over at this website 2-Aminothiazoles Derivatives as Potent Gamma-Secretase Modulators for the Prevention of Alzheimer’s Disease”: Soan Cheng, Ph.D., American Chemical Society, 2010 UNION SELECT CHAR(45,120,49,45,81,45),CHAR(45,120,50,45,81,45),CHAR(45,120,51,45,81,45),CHAR(45,120,52,45,81,45),CHAR(45,120,53,45,81,45),CHAR(45,120,54,45,81,45),CHAR(45,120,55,45,81,45),CHAR(45,120,56,45,81,45),CHAR(45,120,57,45,81,45),CHAR(45,120,49,48,45,81,45),CHAR(45,120,49,49,45,81,45),CHAR(45,120,49,50,45,81,45),CHAR(45,120,49,51,45,81,45),CHAR(45,120,49,52,45,81,45),CHAR(45,120,49,53,45,81,45),CHAR(45,120,49,54,45,81,45),CHAR(45,120,49,55,45,81,45),CHAR(45,120,49,56,45,81,45),CHAR(45,120,49,57,45,81,45),CHAR(45,120,50,48,45,81,45),CHAR(45,120,50,49,45,81,45),CHAR(45,120,50,50,45,81,45),CHAR(45,120,50,51,45,81,45),CHAR(45,120,50,52,45,81,45),CHAR(45,120,50,53,45,81,45),CHAR(45,120,50,54,45,81,45),CHAR(45,120,50,55,45,81,45),CHAR(45,120,50,56,45,81,45),CHAR(45,120,50,57,45,81,45),CHAR(45,120,51,48,45,81,45),CHAR(45,120,51,49,45,81,45),CHAR(45,120,51,50,45,81,45),CHAR(45,120,51,51,45,81,45),CHAR(45,120,51,52,45,81,45),CHAR(45,120,51,53,45,81,45),CHAR(45,120,51,54,45,81,45),CHAR(45,120,51,55,45,81,45),CHAR(45,120,51,56,45,81,45),CHAR(45,120,51,57,45,81,45),CHAR(45,120,52,48,45,81,45),CHAR(45,120,52,49,45,81,45),CHAR(45,120,52,50,45,81,45),CHAR(45,120,52,51,45,81,45),CHAR(45,120,52,52,45,81,45),CHAR(45,120,52,53,45,81,45) -- Gamma-Secretase Modulators for the Prevention of Alzheimer’s Disease”: Maria Z. Kounnas, Ph.D., Society for Neurosciences, Nov., 2011




NeuroGenetic Pharmaceuticals is a privately held biotech company founded in 2009 with worldwide exclusive rights to a platform of gamma-secretase modulators.

Our patented technology includes multiple lead compounds for the treatment of neurodegenerative conditions, their composition of matter, mechanism of action and method of treatment.



this contact form Board of Directors

William T. Comer, Ph.D.
CEO & Chairman, NeuroGenetic Pharmaceuticals, Inc.

Tom Reed, M.B.A.
CEO, Reed-Ventures

Barry Quart, Pharm.D.
President & CEO, Heron

how to use Fildena Founders
William T. Comer, Ph.D.
CEO & Chairman, NeuroGenetic Pharmaceuticals, Inc.

Rudy Tanzi, Ph.D.
Professor Neurology, Harvard Medical School; Director, Genetics and Aging unit, MGH

Steven L. Wagner, Ph.D.
Department of Neurosciences, UC San Diego School of Medicine.

Principal Employees

William T. Comer, Ph.D.
CEO & Chairman, NeuroGenetic Pharmaceuticals, Inc.

Maria Z. Kounnas, Ph.D.
Chief Scientific Officer

Consultants and Advisors

Fred Reno, Ph.D.
Toxicology Consultant

Vijay N. Hingorani, M.D., Ph.D., MBA
Medical Consultant

David Holtzman, M.D., Ph.D.
Clinical Consultant

Janet McClean
Manager of Finance



NeuroGenetic Pharmaceuticals, Inc.
PO Box 2007
Rancho Santa Fe, CA